Target Price | $16.83 |
Price | $8.94 |
Potential |
88.26%
register free of charge
|
Number of Estimates | 15 |
15 Analysts have issued a price target BioCryst Pharmaceuticals, Inc. 2026 .
The average BioCryst Pharmaceuticals, Inc. target price is $16.83.
This is
88.26%
register free of charge
$31.50
252.35%
register free of charge
$11.11
24.27%
register free of charge
|
|
A rating was issued by 18 analysts: 16 Analysts recommend BioCryst Pharmaceuticals, Inc. to buy, 2 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the BioCryst Pharmaceuticals, Inc. stock has an average upside potential 2026 of
88.26%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 450.71 | 626.68 |
36.00% | 39.04% | |
EBITDA Margin | -0.29% | 16.01% |
99.05% | 5,650.67% | |
Net Margin | -19.72% | 4.13% |
71.15% | 120.94% |
14 Analysts have issued a sales forecast BioCryst Pharmaceuticals, Inc. 2025 . The average BioCryst Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an BioCryst Pharmaceuticals, Inc. EBITDA forecast 2025. The average BioCryst Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 BioCryst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average BioCryst Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -0.43 | 0.12 |
63.56% | 127.91% | |
P/E | 72.27 | |
EV/Sales | 3.82 |
15 Analysts have issued a BioCryst Pharmaceuticals, Inc. forecast for earnings per share. The average BioCryst Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
BioCryst Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
B of A Securities |
Locked
➜
Locked
|
Locked | Jul 01 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Jun 30 2025 |
Wedbush |
Locked
➜
Locked
|
Locked | Jun 30 2025 |
Needham |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
Needham |
Locked
➜
Locked
|
Locked | Jun 25 2025 |
Barclays |
Locked
➜
Locked
|
Locked | May 07 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 06 2025 |
Analyst Rating | Date |
---|---|
Locked
B of A Securities:
Locked
➜
Locked
|
Jul 01 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Jun 30 2025 |
Locked
Wedbush:
Locked
➜
Locked
|
Jun 30 2025 |
Locked
Needham:
Locked
➜
Locked
|
Jun 27 2025 |
Locked
Needham:
Locked
➜
Locked
|
Jun 25 2025 |
Locked
Barclays:
Locked
➜
Locked
|
May 07 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 06 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.